# Technology-Assisted Cholesterol Trial in Consumers (TACTiC)

> **NCT04964544** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1196 (actual)

## Conditions studied

- High Cholesterol

## Interventions

- **COMBINATION_PRODUCT:** 5 mg rosuvastatin calcium with a Web App (combination product)

## Key facts

- **NCT ID:** NCT04964544
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-08
- **Primary completion:** 2023-03-01
- **Final completion:** 2023-03-01
- **Target enrollment:** 1196 (ACTUAL)
- **Last updated:** 2024-10-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04964544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04964544, "Technology-Assisted Cholesterol Trial in Consumers (TACTiC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04964544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*